458 results about "Glycoside Compound" patented technology

The invention relates to glycoside-compound conjugates for use in antisense strategies and/or gene therapy. The conjugates comprise a glycoside linked to a compound, in which the glycoside is a ligand capable of binding to a mannose-6-phosphate receptor of a muscle cell. For example the cells are muscle cells of a Duchenne Muscular Dystrophy (DMD) patient and the conjugate comprises an antisense oligonucleotide which causes ex on skipping and induces or restores the synthesis of dystrophin or variants thereof.

There is provided a 5-thio-β-D-glucopyranoside compound of the following formula, which has an inhibitory effect on SGLT2 activity, or a pharmaceutically acceptable salt thereof or a hydrate thereof. There is also provided a pharmaceutical preparation, particularly a prophylactic or therapeutic agent for diabetes, diabetes-related diseases or diabetic complications, which comprises such a compound as an active ingredient.

C-glycoside compounds are suited for stimulating the synthesis of glycosaminoglycans containing a D-glucosamine and/or N-acetyl-D-glucosamine residue, advantageously hyaluronic acid, and/or proteoglycans, advantageously proteoglycans containing hyaluronic acid, by fibroblasts and/or keratinocytes.

The objective of the invention is to provide a photo-aging prophylactic agent for skin with novel ingredients and foods using the photo-aging prophylactic agent for skin, medicaments for mammals including human beings and a skin external agent, as well as feed for mammals. The inventive photo-aging prophylactic agent for skin is characterized by taking extracts of Orobanchaceae plants as effective ingredients. The photo-aging prophylactic agent for skin preferably comprises phenylethanoid glycosides compounds as effective ingredients. Moreover, the photo-aging prophylactic agent for skin preferably comprises at least one of echinacoside and acteoside as the phenylethanoid glycosides compounds. On top of that, the photo-aging prophylactic agent for skin preferably comprises both echinacoside and acteoside as the phenylethanoid glycosides compounds. In addition, the photo-aging prophylactic agent for skin can be employed as medicaments for mammals including human beings, skin external agents, consumptive foods and feed for mammals.

The present invention relates to carbon glycoside compound, and is especially 15-(14-deoxy-11, 12-dehydro)-andrographolide carbon glycoside derivative and its preparation process. The preparation process includes dewatering andrographolide as precursor compound, epoxidation and other reaction to obtain serial andrographolide derivatives; dissolving the derivatives and beta- carbon glycoside ketone in organic solvent and condensation reaction at certain temperature in the presence of catalyst for certain time. The derivative is significant in developing andrographolide.

The present invention relates to novel C-glycoside compounds of given absolute configuration, to a process for synthesising them and to compositions containing them. The invention also relates to the cosmetic use of these C-glycoside compounds as agents to stimulate the synthesis of glycosaminoglycans containing a D-glucosamine and/or N-acetyl-D-glucosamine residue, advantageously hyaluronic acid, and/or of proteoglycans, advantageously proteoglycans containing hyaluronic acid, by fibroblasts and/or keratinocytes. The invention also relates to a cosmetic process for treating keratin materials using a composition containing at least one C-glycoside compound according to the invention.

This invention refers to 17alpha ,22 - dihydroxy Furan Steride compounds and its application. The compound' s structure formula is drawing in right graph, wherein the R1, R2 and R3 = H, C1-10 direct chain, cyclane group or alkenyl , triethylsilyl, dimethyl- tert-butylsilyl-biphenyl-tert-butylsilyl, methoxymethyl or tetrahydropyranyl. R4 = H see right formula a, b, C1-10 direct chain, cyclane group, alkenyl or alkynyl , R5 = C1-10 direct chain or cyclane group, R6 = H, C1-10 direct chain or cyclane group or alkenyl, triethylsilyl, dimethyl- tert-butylsilyl, biphenyl-tert-butylsilyl, methoxymethyl, tetrahydropyranyl. The start materials is diosgenin, which is easy available and cheap. Through F-cyclic degrading, the degradation product' s structure is converted into 17alpha,22 - dihydroxy furan steride compound. The compound again with F-cyclic restructure becomes the sapogenin, which is medicinal value. The process thereof is simple, adapted for industrialized production. It's glycoside of medicinal herbs Chonglou (Paris petiolata bak) sapogenin as one active ingredient, whose synthesis is provided herewith is effectively.

The invention discloses new dihydroiso-coumarin glucoside compounds shown in a formula I, which are extracted and separated from Periplaneta americanna medicinal materials. Through mouse auricle swelling tests, rat granulation tissue hyperblastosis tests and the like, results show that the compounds have effects of resisting inflammation, promoting wounds to heal and the like; and the compounds can be used for preparing medicines for treating inflammation, ulcers, wounds, incised wounds, fistula, burn, scalding and the like, particularly medicines for preventing and treating diseases related to inflammation resistance, promotion of granulation tissue hyperblastosis, wound healing and the like, and have high clinical application value. The invention provides a preparation method for the compounds shown in the formula I.

The present invention relates to new classes of anti-cancer compounds. In particular, the present invention provides glycoside compounds as anti-cancer agent, alone, or in combination with other anti-cancer agents or therapies.

The invention discloses a nano inorganic material and alkyl glycoside compounded radionuclide decontaminant as well as a use method thereof. The decontaminant comprises the following components in parts by weight: 0.5-2 parts of an alkyl glycoside surfactant, 0.1-2 parts of a nano inorganic material additive, 1-5 parts of a chelating agent, 1-5 parts of a corrosion inhibitor, 1-5 parts of a solubilizer, 0.1-1 part of a foam stabilizer and 71-94.4 parts of water and further comprises 0.2-1 part of an anionic surfactant, 0.1-0.5 part of a dispersant, 1-5 parts of an inorganic salt electrolyte, 0.1-0.5 part of a preservative and 0.5-2 parts of a thickener. The use method comprises the step of stirring the mixed components in parts by weight at a high speed to obtain the foam decontaminant. By adopting environment-friendly alkyl glycoside as a foaming agent and simultaneously adding the nano inorganic material which is relatively strong in adsorption capacity and flocculating ability, the nano inorganic material is simple in preparation process, good in radionuclide decontamination effect, free of corrosion on solid surfaces, easily degradable under illumination and less in secondary pollution. The nano inorganic material can be used for defoaming and is convenient to defoam.

The invention provides a phenethyl alcohol glycoside-containing callicarpa kochiana extractive. The main component of the attractive is phenethyl alcohol glycosides compound. The preparation method of the extractive comprises the steps of: extracting the stem leaf of callicarpa kochiana to obtain extracting solution by reflowing water or 50-75% (v/v) alcohol; and purifying the extracting solution with macroporous resin to the extractive, wherein the extractive comprises 40-55% (w/w) forsythoside A and 10-30% (w/w) verbascoside. The animal experiment shows that the extractive can strengthen or improve the learning and memory functions to normal mice and various model animals with damaged memory, and can be used for preparing the medicine for curing the senile dementia and particularly preparing the medicine for curing vascular dementia (VD).

The invention discloses a method for preparing herba epimedii low-glycoside components from herba epimedii. By means of an in-vitro enzymolysis technology, enzymolysis and desugaring are carried out on herba epimedii flavonoid polysaccharide obtained from alcohol extraction herba epimedii decoction pieces, and the herba epimedii low-glycoside components are obtained through conversion. The methodis high in enzymolysis conversion rate, easy and convenient to operate, environmentally friendly, economical and feasible. Polysaccharide substances, such as epmedin A, epmedin B, epmedin C and icariin, in herba epimedii total flavonoids can be completely enzymolyzed and converted into low-glycoside compounds, baohuoside II, sagittatoside A, sagittatoside B, rhamnose-based icarisid II, anhydroicaritin-3-O-rhamnose-dideoxyfuranose and baohuoside I. A stable composition structure ratio is achieved, so that the content of the herba epimedii low-glycoside components is increased.

The invention provides a system integration technology through cell disruption, slurry extraction, membrane separation and macroporous resin adsorption and chromatography separation and purification, high temperature enzyme deactivation and spray drying and the like, which achieves a technical process that from the time fresh cistanche raw materials are fed until obtaining active matters such as monomeric compounds which are rich in echinacoside and verbascoside and the like in 30 to 80 minutes, and the invention effectively overcomes a technical defect that active components such as benzyl carbinol glycosides compounds are normally seriously degraded and lost, which are caused by an enzymatic reaction which is initiated by an imperfect dry treatment method of cistanche, and the invention obviously improves the medical value of cistanche. In the active maters of cistanche which are obtained ( calculating by dry matter), the productivity of echinacoside monomeric compound reaches to 9.8% to 19.6%, and the yield of verbascoside monomeric compound reaches to 2.0% to 7.5%. The content of echinacoside monomeric compound in active matters of cistanche which are obtained reaches to 15% to 49.6%, and the content of verbascoside monomeric compound reaches to 5% to 26.7%.

Novel xylose based glycoside compounds that have xylose linked O-, S- or C-glycosidically to an aglycone containing several aromatic rings, and compositions that comprise the novel xylose based glycosides and non-xylose-based anti-tumor agents, pharmaceuticals or dietary supplements. The compounds or compositions are administered to treat proliferative diseases, including various forms of cancer.

The invention relates to a metal complex of the ouercetin and the glucoside compounds provided with cell apoptosis inducing effect, and the application of the complex in preparing tumor treatment medicine. As reported by experiments, the ouercetin metal complex can inhibit the proliferation of tumor cells, but the uncertainty of the action mechanism restricts the development of the ouercetin metal complex as anticarcinogen medicine. The metal complex of the ouercetin and the glucoside compounds provided with a cell apoptosis inducing effect finds that the metal complex of the ouercetin and the glucoside compounds can induce apoptosis of the tumor cells and can be applied in tumor treatment medicine as a cell apoptosis revulsive.

The invention relates to a method for extracting phenolic glycoside compounds from semen lepidii and application thereof, which can effectively obtain the new function of the semen lepidii. The method adopts the technical scheme that the molecular formula of a semen lepidii new glycoside A is C18H24O12[M+Na]<+>m/z 455.1196; the molecular formula of a semen lepidii new glycoside B is C18H24O12[M+Na]<+>m/z 455.1202. The method has the advantages that two new phenolic glycoside compounds are extracted from a water extract of the semen lepidii, namely the semen lepidii new glycoside A and the semen lepidii new glycoside B; by adopting the two new phenolic glycoside compounds, the cell survival rate of the injured hydrogen peroxide-induced rat myocardial cell H9c2 is obviously improved; the function of protecting the myocardial cell is realized, and a new path is provided for preparation of myocardial protection drugs.

Various glycoside compounds and particularly glycoside compounds which are unstable, easy to oxidize and difficult to dissolve in water and an organic solvent are hydrolyzed under the actions of adsorption, dispersion, curing and settlement of macroporous adsorption resin to generate aglycone or a mixture of the aglycone and secondary glucoside, and the macroporous adsorption resin is secondarily eluted or primarily eluted by using an organic solvent to obtain aglycone, secondary glucoside and a mixture of the aglycone and the secondary glucoside. The invention provides a universal method for preparing the aglycone and the secondary glucoside by using the various glycoside compounds, the method is simple in operation, almost integrated in hydrolysis and separation, high in product purity, good in product yield, free of expensive reagent, capable of realizing repeated utilization of hydrolysate and the macroporous adsorption resin, environment-friendly, easy for realizing industrial production and low in cost and has great advantages as comparison with an enzyme hydrolysis method, a fermentation method and the like. By taking the hydrolysis of the total saponin of panax ginseng as an example, through the hydrolysis of acetic acid and other acids, more prosapogenins Rh2 of panax ginseng and protopanaxadiol aglycones are obtained, but a C17 side chain cyclization product is not obvious.

The present invention belongs to the field of medicine preparing technology, and is especially one kind of figwort total phenyl glycoside compound and its preparation process and application. The figwort total phenyl glycoside has main components of angole glycoside C and ergot sterioside in the weight ratio of 90-95 to 5-10 and total content over 80 wt%. It is prepared through hot alcohol extraction or alcohol percolation. Pharmaceutical experiments show that the figwort total phenyl glycoside can reduce the blood rheology of rat obviously, inhibit platelet aggregation of rat and inferior phlebothrombosis of rat, so that it may be used in preparing medicine for thromboangitis obliterans. It and pharmaceutically acceptable carrier may be form medicine composition capable of being prepared into various preparation forms, such as tablet, capsule, granule, etc.

The invention discloses glycosyl transferase participating in neoandrographolide biosynthesis as well as coding genes and application thereof. The protein provided by the invention is derived from herba andrographitis, and is (a1) or (a5) as follows: (a1) a protein composed of an amino acid sequence shown as a sequence 1 in a sequence table; and (a5) a protein composed of an amino acid sequence shown as a sequence 3 in the sequence table. The invention further discloses application of the protein serving as glycosyl transferase. The glycosyl transferase participates in plant growth and development and secondary metabolism processes. The discovery of the glycosyl transferase and coding genes thereof has important significance. The invention provides a basis for further describing biosynthesis of glycoside compounds in the herba andrographitis, contributes to analyzing a biosynthetic pathway of glycoside active ingredients in the herba andrographitis, and provides novel material basis and gene resources for new drug research and development.

The invention belongs to the field of manufacturing of traditional Chinese medicines, and relates to phenolic glycoside compounds in Paeonia suffruticosa Andr. velamen and novel application of the compounds in anticomplement medicine preparation. According to the invention, a modern pharmacological research method is adopted, dried velamen anticomplement active materials of Paeonia suffruticosa Andr. belonging to Paeonia L. are researched, six phenolic glycoside compounds are separated at an n-butyl alcohol extraction position of a 95% ethanol extract, and the phenolic glycoside compounds are verified to have inhibiting effects on a complement system classical pathway and an alternative pathway. The inhibiting effect CH<50> of the compounds on the complement system classical pathway is 0.062-0.364 mg/mL, and the inhibiting effect AP<50> on the alternative pathway is 0.102-0.566 mg/mL. The compounds can be used to prepare complement inhibitors.